Adalimumab for maintenance of remission in Crohn's disease

Review (6 RCTs; n=1158) found adalimumab is an effective therapy for maintenance of clinical remission in quiescent Crohn’s disease and in patients previously treated with TNF‐α antagonists. However, its effect in the post‐surgical setting is uncertain.

Source:

Cochrane Database of Systematic Reviews